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THERMAL ABLATION ALTERS THE TUMOR MICROENVIRONMENT ACTIVATING A
ROBUST IMMUNE RESPONSE.
Matthew T Campbell, M.D.
Advisor Professor: Padmanee Sharma, M.D Ph.D
Ablation techniques including radiofrequency ablation (RFA) and cryoablation have been
shown to influence the immune system in animal models. Rare abscopal events, a distant
metastatic response to a local procedure, have been observed in humans following both RFA and
cryoablation. These rare observations have led to interest in further defining the impact of
ablation procedures on the immune signature in the tumor microenvironment and in the systemic
circulation.
Retrospectively 9 patients with nephrectomy alone (control) were compared to 16
patients treated with ablation. Gene microarray analysis and immunohistochemistry (IHC) for
presence of immune cell subtypes were performed on the tissue samples. Prospectively, blood
was collected from patients 13 patients who underwent renal ablation for renal cell carcinoma for
stage T1a (less than 4cm) at baseline and at day 1, day 28, and 6 months following the
procedure. The blood was assessed by flow cytommetry and plasma cytokine levels at each time
point following the procedure. GraphPad Prism version 6 was used to perform statistical
analysis. The student’s t-test, Kruskal Wallis test, Friedman’s test, and Dunn’s multiple
comparisons test were used when appropriate.
IHC identified a significant difference (p=0.04) in programmed cell death 1 (PD-1) levels
in the tumor invasive margin when comparing control to ablated tumors, while other tumor stains
showed no significant differences between the two groups. Gene microarray analysis comparing
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control patients to three ablation specimens after RFA found significant differential gene
expression in pathways and processes involving the immune system. Flow cytommetry markers
consistent with previously characterized T regulatory populations of immune cell were found to
trend upward at 24 hours following ablation compared to baseline levels. Cytokine analysis
revealed elevated levels of IL-6 that increased at day 1 and returned toward baseline by day 28.
RFA and cryoablation cause local tissue destruction and an inflammatory immune
response that can be detected by gene microarray. Significant changes in tissue IHC, plasma
cytokine levels, and immune cell populations in peripheral blood flow cytommetry analysis were
not detected.
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I.

Background:
Thermal ablation refers to interventional procedures that use extreme temperature to

cause local tissue damage. The two most common procedures employing extreme temperature
consist of radiofrequency ablation (RFA) and cryoablation. Both procedures introduce a metal
probe into a tumor using direct visual or imaging guidance with either ultrasound or computated
tomography (CT) guidance. Using two temperature extremes, burning tissue in RFA and
freezing tissue in cryoablation, small tumors in a number of important anatomical locations can
be effectively destroyed. In terms of local treatment strategies, cryo-ablation is an attractive
treatment modality for the following reasons: 1) It has been shown to be safe and effective in
treating kidney, liver, bone, lung, adrenal and soft tissue masses; 2) It is palliative with the
freezing procedure causing a local analgesic effect; 3) It has been shown to be potentially costeffective in oligometastatic disease 1. Cryosurgery has been interesting to immunologists and
oncologists for decades due to a rare Abscopal type of effect witnessed in several case reported
prostate and breast cancer patients 2 3. Cryo-ablation induces membrane disruption, solution
effects, organelle disruption, ice crystallization, and microvascular thrombosis 4. Depending on
the proximity to the cryo-probe, cells appear to be influenced by the different insults in varying
degrees. In sum, certain cells appear to experience a necrotic cell death, while others undergo
apoptosis. The mechanism of cell death appears to be important in optimally stimulating an
immune response. In an in vitro system evaluating the maturation of immature dendritic cells,
adding living fibroblasts and apoptotic fibroblasts yielded no maturation, while adding necrotic
fibroblasts resulted in significant maturation 5. Using bone marrow-derived murine macrophages
stimulated by either tumor cells undergoing UV induced apoptosis or cryotherapy induced
necrosis, Reiter et al found macrophages exposed to necrotic cells exhibited significant antitumor
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effect while those exposed to apoptotic cells were immunosuppressed 6. Work by Sauter et al.
found immature dendritic cells (DCs) are capable of phagocytosis of both apoptotic and necrotic
tumors cells allowing for cross presentation to CD8+ T cells. Only necrotic tumor cells and a
supernatant generated from necrotic tumor cells were capable of maturing DCs allowing for
activation of resting CD4+ and CD8+ T cells thus mounting a specific anti-tumor response.
Apoptotic cells and a supernatant generated from apoptotic cells were not capable of inducing
this maturation 7.
Whether the creation of therapeutic apoptosis or necrosis in tumor cells is
immunosuppressive or immune-stimulatory has led to much debate. The danger theory proposed
by Polly Matzinger broke from the traditional model that the immune system’s main role is to
recognize self vs non-self. In her model, Matzinger proposed the immune system is designed to
recognize cell injury as danger and to react to these insults 8. Necrosis leads to the denaturing of
proteins and break down of the cell wall integrity leading to the release of important
inflammatory molecules including High mobility group 1 (HMGB1), uric acid, and heat shock
proteins (HSP) including hsp70, hsp90, calreticulin, and gp96 9,10 11. Scaffidi et al, found that
HMGB1 was important for inducing inflammation and enhanced DC maturation, while apoptosis
primary or secondary did not release HMGB1 10. Basu et al. found the release of HSP induced
macrophages to secrete cytokines and induced maturation of DC interacting through the NF-κB
9

. Shi et al. identified uric acid as an important molecule in dendritic cell maturation 11. Scheffer

et al. tested apoptotic and necrotic tumor cells injected into a murine model followed by live
tumor cell injection and found apoptotic cells induced significant protection and prolonged
survival, while necrotic cell vaccine provided little protection 12. Conversely, Kotera et al.
found pulsing dendritic cells with apoptotic cells produced by ultraviolet B exposure or necrotic
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cells produced via freeze/thaw cycles produced equivalent dendritic cell activation and similar
anti-tumor effect 13. Gamrekelashvili et al. used ganciclovir to induced tumor cell apoptosis and
a vascular targeting drug, ZD6126, to procedure necrotic tumor cells. In these experiments, the
group found when transferring lymphocytes from the spleen and tumor draining lymph nodes to
other tumor bearing mice, mice receiving cells from the ganciclovir treated mice were afforded
protection while no protection was provided to the mice receiving cells from mice treated with
ZD6126. The authors showed this protection was conferred by the CD8+ T cells 14. Feng et al.
found a significant difference in the immunostimulatory nature of non-stressed and heat-stressed
apoptotic leukemic cells, with heat-stressed cells capable of inducing maturation of dendritic
cells 15. As a result of these studies, the context and rapidity of induction of necrotic and
apoptotic cells appears to be important in the generation of an immune-reactive or
immunosuppressive response.
Kolicher is credited by Strauss as introducing electrocoagulation (surgical diathermy) to
inoperable cancer in 1910 16. In the same publication, Strauss reported his experience treating
rectal carcinoma with surgical diathermy he wrote:
“Clinically the results are remarkable. After the first or second application of diathermy
the patient gains weight and the hemoglobin and red cell content and red cell count of the
blood are increased to normal levels. Even a patient who has lost a great deal of weight
or is cachectic loses all the appearances that are characteristic of a person with advanced
carcinoma.”16

In this work, Strauss hypothesized the reticulo-endothelial system was involved in the dramatic
responses seen in patients treated with this approach. Using pigs, McGahan et al. studied the
local effects of radiofrequency ablation (RFA) via ultrasound and under both gross and
microscopic dissection at autopsy 17. At the site of the RFA probe a central char was observed.
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This char was surrounded by an area of cells that undergo necrosis, the third outer area contained
areas of hemorrhage and congestion. The injury evolved over the period of weeks with
eventually the area being walled off with granulation tissue and chronic inflammatory cells
leading to scar.
Using a VX2 hepatoma model in rabbits, Wissniowski et al. found animals treated with
RFA compared to observation had a significant infiltration of T cells within the tumors and
evidence of persistent specific circulating T cells 18. den Brok et al. using a murine model
injecting B16-OVA melanoma cells into the flank that RFA alone protected 20% of animals
repeated B16-OVA cellular rechallenge in the contralateral flank, but did not protect against
challenge with a thymoma cell line. This protection was transferrable to other animals when
splenocytes were transferred and was significantly reduced when plasma was used, indicating
that the cellular portion of the immune arm provided the effect. Also, RFA combined with
CTLA4 blockade was more effective than RFA alone in protecting animals against tumor
rechallenge and greatly enhanced survival 19. Radiofrequency ablation in a murine urothelial
carcinoma model generated systemic T cell responses with increased infiltration of dendritic
cells within the tumors 20.
In humans, RFA in metastatic liver tumors compared to RFA in localized hepatocellular
carcinoma (HCC) tumors produced evidence of trafficking T cells from the systemic circulation
to the tumor site with a period of decreased T cells in the peripheral circulation. The T cells in
the tumors were found have a strong proliferative response and produced the Th1-associated
cytokine, IFN-γ, to tumor associated antigen MUC1

21

. In an additional study of 12 patients, 6

with HCC, 6 with metastatic colorectal cancer to the liver, RFA to the liver lesion produced T
cells in the peripheral circulation that were specific and produced IFN-γ were significantly
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elevated at both 4 and 8 week time points after the procedure 22. In a study of 20 patients with
localized HCC unfit for liver transplantation or surgical resection, RFA produced increased
frequency of circulating IFN-γ producing specific T cells. However, despite the presence of
these cells, patients were not protected against relapse from HCC 23. Zerbini’s group later
showed in a group of 20 patients the necrotic tissue collected immediately following RFA for
HCC are capable of inducing maturation of antigen presenting cells (APCs) capable of producing
specific T cells for HCC

24

.

Animal modeling has found cryosurgery under certain conditions to be
immunostimulatory and others immunosuppressive 4,25. Both Sabel and Sidana reviewed the
animal modeling systems that have explored cryoimmunology and provide summaries of these
experiments. The initial studies evaluating the immune response to cryoablation involved using
a rabbit model subjected to cryoablation of the male sex organs resulting in a the production of
tissue specific auto-antibody response26,27. Myers et al. used multiple mouse types with both
fibrosarcoma and mammary cell tumor types and found cryosurgery was more protective against
rechallenge with the same tumor type than to amputation or control, but was unable to protect
against rechallenge with a different tumor type 28. Using a rat model, Blackwood et al. found
that animals who received cryoablation of both myosarcoma and carcinosarcoma cell linederived tumors were protected against tumor rechallenge and intraperitoneal implantation 29.
Neel et al. compared mice with virally induced mammary adenocarcinoma or chemically
induced sarcoma treated with surgery, cryoablation, or ligation and found mice treated with
cryoablation had longer time until tumor recurrence and improved survival after tumor
rechallenge 30. Bagley et al. compared mice with chemically induced limb sarcoma treated with
cryosurgery, observation, amputation and harvested splenic lymphocytes. The splenic
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lymphocytes from the cryosurgically treated animals had specific cytotoxicity against the
chemically induced sarcoma cell lines, but less so against other cancer cell lines 31. In a rat
model using metastasizing rat's mammary tumor (MRMT-1), cryosurgery was compared to
surgical excision and using the Winn neutralization assay was found to initially be less
immunosuppressive than surgery alone. Based on these findings, the authors concluded the
underlying immunosuppressive nature of cryosurgery was related to the development of a
suppressor cell response 32.

Using the same rate model, Misio et al. found animals treated with

cryosurgery had evidence of tumor regression and protection against the development of lung
and lymph node metastasis, which peaked at 10 weeks following the procedure. In contrast,
animals treated with surgical excision had continued progressive risk of developing lung and
lymph node metastasis that increased with time 33.
In a study of 20 patients with high risk localized prostate cancer treated with
cryoablation, patients’ serum cytokine levels and immune cyto-lytic activity was assessed at
baseline, after 4 weeks and after 8 weeks 34. The serum cytokines of interest included classic
Th1 cytokines interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) and classic
Th2 cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10) with the authors evaluating the
Th1/Th2 ratio of IFN-γ/IL-4. The authors found the Th1/Th2 ratio was increased at 4 weeks, but
diminished at 8 weeks, suggesting the response was favorable, but not sustained. The T cells
were also found to be cyto-lytic to a prostate cell line and not to a renal cell carcinoma cell line
supporting specificity of response.
In renal cell carcinoma (RCC), the ratio of Th1 to Th2 cytokines produced by T cells has
been found to inversely correlate with tumor grade and stage 35. Murine modeling has found
diminished Th1 cytokine production and responsible T cell subset presence during tumor

7

progression 36. Alternatively, tipping the balance to more Th1 cytokine production as compared
to Th2 can lead to tumor regression 37.
In an in vivo melanoma mouse model, the authors sought to further understand
mechanisms of influencing the immune system in animals treated with cryosurgery,
radiofrequency ablation and tumor vaccination. Both RFA and cryosurgery appeared to produce
an in situ depot of tumor antigen and debris. The authors used an indium labeled tracer, which
was injected into the tumor. Animals were then treated with a dendritic cell vaccine,
radiofrequency ablation, cryoablation, or surgical resection. The authors found within tumor
draining lymph nodes of animals treated with cryosurgery an increase in immature dendritic cells
which took up tumor antigen as well as mature dendritic cells. The cryosurgery group was more
resistant to tumor rechallenge and had the longest survival compared to all other animal groups
included on study. The authors also found the addition of anti-CTLA4 to cryosurgery or
radiofrequency ablation resulted in a significant survival advantage after tumor re-challenge
compared to animals treated with anti-CTLA4 alone, RFA alone, or cryosurgery 19.
Within our current group at MD Anderson Cancer Center, work published by Dr. Matin
showed the immunogenicity of cryosurgery in an orthotopic renal cell carcinoma mouse model.
In this model, cryosurgery of a renal cell carcinoma harboring kidney led to significant
infiltration of inflammatory cells including neutrophils, macrophages, and T cells compared to
kidneys harboring renal cell carcinoma.18 Dr. Allison and his previous group at Memorial Sloan
Kettering investigated pairing cryosurgery with ipilimumab in a TRAMP prostate cancer mouse
model. In this model, mice received a thigh injection with TRAMP C2 cells, one month before
undergoing cryo-surgery or a sham procedure on the resulting mass. The mice were then
rechallenged the following day with an additional TRAMP C2 cell injection in the opposite
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thigh. The mice were then either treated with ipilimumab or placebo. Finally a subset of mice
received an anti-CD8 T cell antibody prior to cryosurgery and then at specific intervals during
the study. The mice treated with the combination of cryosurgery and ipilimumab had a
synergistic response with a significant delay in tumor re-growth and the longest overall survival
within the study groups. T cells found in mice from the cryosurgery plus ipilimumab group were
specific against the TRAMP C2 cells. These T cells were also active with high levels of IFNgamma detected in both the secondary tumors and spleens of the mice studied. In contrast, mice
treated with cryosurgery alone, ipilimumab alone, or cryosurgery combined with ipilimumab and
anti-CD8 T cell antibody had a shortened time until tumor recurrence and a shorter survival
compared to the ipilimumab plus cryosurgery group. The authors concluded cryosurgery and
CTLA-4 blockade in the TRAMP prostate cancer mouse model produced increased ratio of
effector CD8 T cells compared to T regulatory cells, and provided a synergistic response in mice
with observed systemic, specific immunity.19
Currently, two classes of immune check point inhibitors have achieved FDA approval.
The anti-CTLA-4 targeting antibody, ipilimumab was the first drug to show significant survival
advantage in patients with metastatic melanoma leading to its FDA approval in this setting 38 .
The second class targeting the PD-1/PDL-1 interface, with antibodies developed and tested in
clinical trials leading to FDA approval in advanced melanoma and metastatic squamous cell
carcinoma of the lung, with active testing in many additional tumor subtypes 39 40 41 42 43 44. All
of these agents showed exciting activity with subsets of patients experiencing durable responses.
In the setting of mRCC, fewer patients have been enrolled on studies involving the
immune check point inhibitors compared patients with advanced melanoma. In the smaller
sample sizes, both the agents targeting CTLA-4 and PD1/PDL-1 appear of similar to reduced
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efficacy in mRCC as found in melanoma. Granted, phase I trials assess safety and dose as the
primary endpoints, but in each trial efficacy was a secondary endpoint. In the phase I trial
evaluating ipilimumab, there was a response rate of 9.8%(6 of 61 pts) for all patients treated,
though this increased to 12.5% (5 of 40pts) in the subset treated with maximum dosing 10mg/kg
45

. In the phase I anti-PD-1 study, patients with mRCC had a 27% response rate (9 of 33pts) 42.

Finally, in the anti-PD-L1 study, patients with mRCC had a response rate of 11.7% (2 of 17pts)
46

. Our group has significant experience with the use of the immune check point inhibitors in

clinical trials. Dr. Sharma served as a co-led author on preoperative CTLA-4 blockade 47 48. We
currently have within the GU department a phase II trial evaluating ipilimumab plus androgen
deprivation in prostate cancer, a phase I clinical trial evaluating nivolumab in combination with
sunitinib, pazopanib, or ipilimumab in patients with mRCC, and are participating in the phase III
trial PDL-1 vs. everolimus in patients with mRCC.
In the United States, in 2015, roughly 60,000 individuals will be diagnosed with a renal
or renal pelvis neoplasm and 15,000 will die from these malignancies 49. Renal cell carcinoma
(RCC) represents the vast majority of these cases with the clear cell subtype being the most
common histology accounting for 80% of RCC cases. Surgical management for localized RCC
remains the treatment of choice though 30% of patients with localized disease are destined to
recur. Metastatic RCC (mRCC) is considered largely incurable. When patients with mRCC
have long term disease free survival they typically have oligometastatic disease and are cured
with aggressive surgery or when they have a complete response to an immunotherapy, which
currently represents approximately 5%-10% of patients.

Immunotherapy was initially explored

in mRCC in the form of cytokine therapy with high dose interleukin-2 (HD-IL-2) and interferonalpha (IFN-α) as all standard combination chemotherapy approaches and radiation treatments
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were proven ineffective in the metastatic setting 50 51 52. With HD-IL-2, 5-7% of patients with
mRCC will have a complete response and even with prolonged follow up for well over a decade
without relapse. Complete responses are restricted to clear cell histology and are most common
in patients who have had a previous nephrectomy (removal of primary tumor) and in patients
with lung only metastasis.
Though 7 agents have received United States Food and Drug Administration approval for
the treatment of metastatic renal cell carcinoma over the last decade, none of these agents (all
targeting either the vascular endothelial growth factor axis or mammalian target of rapamycin
pathway) offer cure. Continuing to expand the pool of patients responsive to immunotherapy is
paramount to increasing the potential cure fraction for patients with mRCC. Cryoablation and
radiofrequency ablation are procedures readily available across the clinical spectrum. At MD
Anderson Cancer Center, a clinical trial investigating the use of a monoclonal CTLA-4 targeting
antibody, tremelimumab, with or without cryoablation is planned. In an effort to study the
impact of cryoablation alone we sought to perform both retrospective and prospective analysis of
patients who received thermal ablation at UT MD Anderson Cancer Center.
Based on this evidence, the central hypothesis of my project is thermal ablation
procedures cause a significant local inflammatory response leading to an immunogenic gene
signature that will be confirmed with detectable changes in immune cells identified in tissue and
in the peripheral circulation. In order to test this hypothesis the following aims were studied:
1. To determine in a retrospective cohort of patients treated with thermal ablation followed
by nephrectomy if an inflammatory, immunogenic signature is detected compared to
patients treated with nephrectomy alone.
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2. To determine in a retrospective cohort of patients if there is a correlation between the
gene signature produced with thermal ablation followed by nephrectomy with changes
detected in immunohistochemistry for specific immune cell subsets compared to patients
treated with nephrectomy alone.
3. To determine in a prospective cohort of patients if thermal ablation produces detectable
changes in peripheral blood immune cell subsets and cytokine levels that can be detected
over one day, four weeks, and a 6 month timeframe.
II.

Material and Methods
At UT MD Anderson Cancer 17 patients who underwent an ablative procedure from

2004 to 2012 and later underwent a nephrectomy were retrospectively analyzed on protocol PA09-0383. The nephrectomy samples were compared to 9 patients who received nephrectomy
alone using immunohistochemical studies and gene microarray analysis. On a separate arm of
PA-09-0383, 13 patients who underwent an ablative procedure to the kidney were prospectively
analyzed using blood based studies.
Immunohistochemistry
After nephrectomy, the specimen was formalin fixed and paraffin embedded.
Appropriate blocks of tissue were selected by Dr. Priya Rao of the genitourinary pathology
department. Dr. Jorge Blando of the immunotherapy platform sliced the tissue into 5 μm
sections. Immunohistochemistry stains for CD3, CD4, CD8, CD20, CD45RO, CD57, CD68,
FoxP3, Granzyme B, PD-1, and PD-L1 were performed as per protocol on the immunotherapy
platform at UT MD Anderson Cancer Center. The selection of these antibodies allowed for
enumeration of specific T cell subsets CD3, CD4, CD8, CD45RO, regulatory T cell subset
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FoxP3, cytotoxic cells Granzyme B, and the immune checkpoint axis PD-1 and PD-L1. CD3,
CD4, CD8, CD20, CD45RO, CD57, CD68, FoxP3, Granzyme B are validated antibodies. PD-1
and PD-L1 staining was confirmed by two pathologists Dr. Jorge Blando and Dr. Ignacio
Wastuba. If a discrepancy in scoring of staining existed, both pathologists reviewed the slides
together to come to consensus. Briefly, sections of 5 μm thickness were selected placed on
charged slides heated overnight and then were deparaffinized using xylene and graded alcohols.
Slides were then placed in a DAKO HipH buffer solution and heated to 97°C for 15 minutes.
The slides were then incubated overnight with the primary antibody at 5°C. The following
morning the Powervision kit (Vision Biosystems) was used as the secondary antibody. Exposure
to diaminobenzidene served as the chromogene and counterstaining was performed using
hematoxylin. All tissue specimens were then evaluated using hematoxylin-eosin (H&E)
staining. A Leica system using Aperio software was used to tabulate the total number of stained
cells/mm3 per 5 high power fields (HPF) at 20x magnification. The PD-L1 h-score was
calculated by taking the PDL-1 epithelial stained cells/PDL-1 tumoral stained cells. Control
patients received nephrectomy alone, ablation or treatment refer to patients who received an
ablation procedure followed later by nephrectomy. Distant refers to patients who underwent a
non-renal ablation followed later by nephrectomy; local refers to patients who received ablation
to the kidney followed by nephrectomy, which was either partial or radical.
Peripheral Blood Collection and Processing
Blood was collected as per Dr. Padmanee Sharma’s laboratory protocol. Blood was
drawn into BD Venous Blood collection heparinized green top tubes. Tubes were spun down at
400 times gravity for 20 seconds and placed into polypropylene conicals. The conicals were then
spun at 410 times gravity for 10 minutes. The plasma layer was then collected and spun at 885
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times gravity for 10 minutes. Aliquots of plasma were collected and placed into cryogenic vails
and NUNC tubes. Plasma was then diluted in a 1:1 ratio with Roswell Park Memorial Institute
(RPMI) medium (Cellgro). Ficolling blood was performed using Leucosep tubes. In brief 15mL
of lymphocyte separation medium (LSM) (Cellgro) was added to the Leucosept tube and
centrifuged for 1 minute at 400 times gravity. After centrifuging was completed, 35mL of
plasma was added to Leucosept tube and centrifuged at 1000 times gravity for 12 minutes. The
plasma layer was then removed to the level of 1cm above the lymphocyte layer. The lymphocyte
layer was then collected into 50mL polypropylene conical tube. The volume was then brought to
50mL with RPMI medium. The tube was then spun at 400 times gravity for 15 minutes. The
supernatant was decanted and the pellet was gently resuspended. To remove any residual red
blood cells, 30mL of ammonium chloride lysis buffer was added to the resuspended pellet. The
tube was then spun at 450 times gravity for 6 minutes. The pellet was then harvested. All
resuspended pellets were combined into a 50mL polypropylene conical tube and brought to
50mL volume with RPMI. A 20μL aliquot was collected in a 12 x 75mm test tube and added to
20 μL of 0.4% Trypan Blue (BioWhittaker). The cell suspension concentration was determined
with a hemacytometer. Peripheral blood mononuclear cells (PBMCs) were isolated from plasma.
Flow Cytommetry
The following antibodies were used for flow cytommetry CD3 FITC, CD4 AmCyan, CD8 APC,
CD19 FITC, (BD PharMingen), CD45RO Pacific blue (Biolegend) ICOS PECy7 (eBioscience),
FoxP3 PE (eBioscience), CD25 APC (EBioscience), LAP APC (R&D FAB), CD127 eflour 450
(eBioscience), CD33 eflour 450 (eBioscience), CD14 PECy7 (eBioscience), CD16 APCCy (BD
PharMingen, CD56 Pacific blue (Biolegend), CD11b APC (EBioscience). Intracellular staining
for FoxP3 was performed using manufacturer guidelines. The antibodies were selected to
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enumerate the presence of T cells, T cell subsets including potential regulatory and effector
subsets, macrophage, myeloid derived suppressor cells, and dendritic cells. Samples were
analyzed using the FACSCanto II (Becton Dickinson) and data were then analyzed using BD
FACSDiva software.
54 47

Gates were selected based on isotype controls as previously published 53

. All samples were tested in triplicate.

Cytokine Analysis
Patient plasma was used to perform cytokine analysis using the Meso scale discovery
Th1/Th2 kit. 55 Samples were prepared and tested in triplicate as per manufacturer’s guidelines.
Cytokines tested included interferon gamma (IFN-γ), interleukin-2 (IL-2), interleukin-4 (IL-4),
interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12p70 (IL-12p70),
interleukin-13 (IL-13), tumor necrosis factor alpha (TNF-α). These cytokines were selected to
quantify a variety of known Th1 and Th2 related cytokines. Appropriate standards were used.
The kits were analyzed on MDS QuickPlex SQ 120 per manufacturer’s guidelines. All samples
were tested in triplicate.
Gene Microarray Analysis
Total RNA was extracted from renal cell carcinoma (RCC) tissue using miRNeasy Kit (Qiagen).
The gene expression was assessed by Affymetrix’s GeneChip Human 2.0 ST Array. Data was
analyzed using the Ingenuity Platform Analysis as previously described 56.
Statistical Analysis
Data were collected with Microsoft Excel. All analysis was conducted using GraphPad
Prism version 6 and SAS 9.4 software. Due to the small sample sizes, non-parametric analysis
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was conducted. For immunohistochemistry, the student’s t test, Kruskal Wallis, and Dunn’s
multiple comparison’s test were used to analyze the data. The gene microarray analysis was
conducted using the Ingenuity pathway analysis. When comparing the normal renal tissue to
renal cell carcinoma tissue, a fold cutoff of ±2 and p value cut off of 0.05 was employed
allowing for a false positive call rate of 25%. When comparing nephrectomy only to patients
who underwent ablation prior to nephrectomy, a fold cutoff of ±1.5 and p value cut off of 0.05
was used again allowing for a false positive call rate of 25%. The beta-uniform mixture model
(BUM model) was used to generate a histogram of the p values generated for the differentially
expressed genes assuming a normal distribution. For the flow cytommetry analysis and cytokine
analysis the Friedman test was used to test for differences among groups when samples were
matched over various time points, the Kruskal Wallis was used when samples were not matched
to determine significant between groups, and the Dunn’s multiple comparisons test was used
between to test for differences between multiple groups. A one sided p value of 0.05 was used to
reject the null hypothesis.
III.

Results

Clinical Characteristics
Clinical characteristics for patients on the retrospective portion of the study are shown in
Table 1. Clinical characteristics for patients on the prospective portion of the study are shown in
Table 2.
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Age (years)
Race
Caucasian
Black
Hispanic
Histology
Clear Cell
Other
Clinical T Stage
T1a
T1b
≥T2
Unknown
Pathologic T Stage
T1a
T1b
T2
T3a
Metastatic Disease
No
Yes
Time (Ablation to
Surgery) years
< 1 year
 1 year

Nephrectomy
Only
N=9
67±11.9

Radiofrequency
Ablation
N = 11
64±10.8 years

Cryoablation
N=6

4 (44%)
2 (22%)
3 (33%)

9 (82%)
1 (9%)
1 (9%)

4 (67%)
0
2 (33%)

8 (89%)
1 (11%)

9 (82%)
2 (18%)

6 (100%)
0

6 (67%)
3 (33%)
0
0

7 (64%)
2 (18%)
0
2 (18%)

3 (50%)
3 (50%)
0
0

6 (67%)
3 (33%)
0
0

8 (73%)
2 (18%)
0
1 (9%)

2 (33%)
3 (50%)
0
1 (17%)

9 (100%)

8 (73%)
3 (27%)

3 (50%)
3 (50%)

1.6 ± 1.6
4 (36%)
7 (64%)

0.9 ± 1.6
4 (66%)
2 (33%)

66±7.3 years

Table 1 Clinical Characteristics of Retrospective Patients: Nephrectomy Only (control),
radiofrequency ablation followed by nephrectomy, and cryoablation followed by nephrectomy
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Age (years)
Race
White
Hispanic
Histology
Clear cell
Other
Clinical Stage
T1a
Von Hippel Lindau
Yes
No

Radiofrequency Ablation
N=8
64 ± 13

Cryoablation
N=5
71 ±12.8

7 (87%)
1 (13%)

3 (60%)
2 (40%)

6 (75%)
2 (25%)

5 (100%)
0%

8 (100%)

5 (100%)

1 (13%)
7 (87%)

1 (20%)
4 (80%)

Table 2 Clinical Characteristics: Prospective patients treated with ablation followed by serial
blood draws.
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Gene Microarray Analysis
The gene microarray analysis was performed through the Ingenuity Pathway Analysis
(IPA). The initial unbiased analysis of both tumor tissue versus normal tissue and ablated tissue
vs. control tissue was carried out using 10 tumor samples and 8 normal kidney specimens. A
total of 719 genes were found to be differentially expressed between the normal and tumor
tissue. Using a fold cutoff of ±2 and p value cut off of 0.05 allowing for a false positive call rate
of 25%, 195 genes were found to have a significant positive change in expression and 524 were
found to have a negative change in expression. Table 3 shows the 20 most up-regulated
pathways involved, Table 4 shows the 10 most positive differentially expressed genes and table 5
shows the 10 most negative differentially expressed genes. Ingenuity groupings of genes
includes location, pathways involved, processed involved, diseases involved, and interaction.
For example a pathway normally involves signaling, processes involve transport/activation, and
interaction involves the number of other genes an individual gene influences or is influenced by
according to Ingenuity.
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Pathways

DEGs

pValue

LPS/IL-1 Mediated Inhibition of RXR Function

23

4.70868E-06

Glycine Betaine Degradation

5

1.25694E-05

Complement System

7

0.00013831

α-tocopherol Degradation

3

0.000177904

Coagulation System

7

0.000204598

Xenobiotic Metabolism Signaling

23

0.000280209

4-hydroxyproline Degradation I

2

0.0012802

β-alanine Degradation I

2

0.0012802

Sucrose Degradation V (Mammalian)

3

0.002235949

PXR/RXR Activation

8

0.002620771

Valine Degradation I

4

0.003336923

FXR/RXR Activation

9

0.003611253

Methionine Salvage II (Mammalian)

2

0.003749206

Atherosclerosis Signaling

11

0.004123248

LXR/RXR Activation

11

0.004123248

Retinoate Biosynthesis I

5

0.005232584

Uracil Degradation II (Reductive)

2

0.007320507

Arginine Degradation I (Arginase Pathway)

2

0.007320507

Thymine Degradation

2

0.007320507

D-glucuronate Degradation I

2

0.007320507

Table 3: Tumor Tissue versus Normal Tissue Top 20 Pathways Upregulated
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Symbol: Name

Fold Change

Notes

Location

Pathways

Processes

Diseases

Interactions

0

Molecular
Function
Other

TNFAIP6: tumor necrosis
factor, alpha-induced
protein 6
C3: complement
component 3
LOX: lysyl oxidase

10.59

Extracellular
Space

1

6

4

2

9.325

1

Peptidase

5

114

41

13

5.61

1

Enzyme

1

23

14

4

LAMA4: laminin, alpha 4

4.639

1

Enzyme

0

13

18

0

FABP4: fatty acid binding
protein 4, adipocyte
NNMT: nicotinamide Nmethyltransferase
ST8SIA4: ST8 alpha-Nacetyl-neuraminide alpha2,8-sialyltransferase 4
HILPDA: hypoxia inducible
lipid droplet-associated
DNAH11: dynein,
axonemal, heavy chain 11
EBF2: early B-cell factor 2

4.639

1

Transporter

Extracellular
Space
Extracellular
Space
Extracellular
Space
Cytoplasm

1

51

17

5

4.513

1

Enzyme

Cytoplasm

0

1

12

1

4.504

0

Enzyme

Cytoplasm

0

18

0

2

4.466

1

Other

Cytoplasm

0

1

7

1

4.048

1

Enzyme

Cytoplasm

0

2

14

0

4.036

1

Other

Nucleus

0

13

10

0

Table 4: 10 Most up-regulated genes comparing renal cell carcinoma tissue to normal tissue
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Symbol: Name

Notes

EGF: epidermal growth factor

Fold
Change
-13.691

Location

Pathways

Processes

Diseases

Interactions

Extracellular
Space
Unknown

30

120

19

31

1

Molecular
Function
growth
factor
Other

MT1H: metallothionein 1H

-16.098

ALDOB: aldolase B, fructosebisphosphate
SCNN1G: sodium channel, nonvoltage-gated 1, gamma
subunit
MUC15: mucin 15, cell surface
associated
MT1G: metallothionein 1G

-16.969

0

36

20

4

1

Enzyme

Cytoplasm

4

2

8

5

-20.544

0

ion channel

Plasma
Membrane

2

25

9

6

-21.564

0

Other

0

0

0

0

-22.472

1

Other

Extracellular
Space
Unknown

KNG1: kininogen 1

0

0

9

1

-37.356

1

Other

8

85

18

13

UMOD: uromodulin

-46.644

1

Other

0

33

25

3

AQP2: aquaporin 2 (collecting
duct)
SLC12A1: solute carrier family
12 (sodium/potassium/chloride
transporters), member 1

-48.554

0

Transporter

1

9

8

5

-74.282

1

Transporter

Extracellular
Space
Extracellular
Space
Plasma
Membrane
Plasma
Membrane

1

33

28

3

1

Table 5: 10 most down regulated genes comparing renal cell carcinoma tissue to normal tissue
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For Ingenuity pathway analysis for ablation versus nephrectomy only, a fold change cut
off of ±1.5 p≤0.05 was used to detect differentially expressed genes with again a false positive
call rate of 25%. A total of 10 nephrectomy alone patients and 5 nephrectomy following ablation
patients were used for this analysis. A total of 495 differentially expressed genes were
identified in this analysis. Table 6 shows the top 20 pathways altered by ablation as compared to
nephrectomy alone. The Table shows the number of differentially expressed genes and the
cumulative significance of the pathway. Of note, 9 pathways are directly involved in immune
cell quantity, movement, connectivity, and function. Of particular interest is the connection
between innate and adaptive immunity and dendritic cell maturation. Table 7 shows the top 30
biologic processes and is represented in similar fashion as table 6. Every biologic process
represented is involved in immune response. Table 8 and Table 9 detail the top 20 up-regulated
and top 20 down-regulated genes respectively. Both tables are designed in the same format as
Table 5 discussed above. Whether the differences in groups reflects biologic differences,
differences in immune cell infiltrate, or differences in the tumor stroma are not known or
characterized in our analysis.
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Pathways
Atherosclerosis Signaling
Granulocyte Adhesion and Diapedesis
PI3K Signaling in B Lymphocytes
Inhibition of Matrix Metalloproteases
Leukocyte Extravasation Signaling
Phospholipases
Eicosanoid Signaling
Dendritic Cell Maturation
Caveolar-mediated Endocytosis Signaling
Agranulocyte Adhesion and Diapedesis
Airway Pathology in Chronic Obstructive Pulmonary Disease
Axonal Guidance Signaling
Gαq Signaling
Prostanoid Biosynthesis
Crosstalk between Dendritic Cells and Natural Killer Cells
Communication between Innate and Adaptive Immune Cells
Endothelin-1 Signaling
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid
Arthritis
D-myo-inositol (1,4,5)-Trisphosphate Biosynthesis
Phospholipase C Signaling

Table 6: Top 20 Pathways Altered by Ablation versus surgery alone

DEGs
15
17
14
8
17
9
8
13
8
13
3
22
11
3
8
8
11
16

pValue
2.05E-07
9.32E-07
2.41E-06
3.26E-06
5.95E-06
7.77E-06
0.000111
0.00037
0.000385
0.000508
0.0007
0.000713
0.00089
0.001031
0.001422
0.001527
0.002822
0.002935

4
13

0.003688
0.004362
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Biological Process
cell movement of leukocytes
leukocyte migration
cell movement of myeloid cells
quantity of leukocytes
cell movement of granulocytes
proliferation of lymphocytes
cell movement
proliferation of blood cells
proliferation of immune cells
infiltration of cells
cell movement of phagocytes
infiltration of leukocytes
shape change of leukocytes
cell death of immune cells
migration of cells
function of leukocytes
cell movement of neutrophils
cell death of blood cells
inflammatory response
cell movement of mononuclear leukocytes
activation of leukocytes
antibody response
migration of mononuclear leukocytes
Necrosis
binding of cells
quantity of lymphocytes
cell movement of lymphocytes
activation of cells
quantity of T lymphocytes
proliferation of T lymphocytes

DEGs
75
80
57
78
44
65
123
71
68
44
53
42
20
59
111
53
36
60
60
46
57
26
39
136
47
59
40
71
49
52

pValue
9.88421E-22
6.26341E-21
4.45404E-19
5.18822E-18
3.89424E-17
1.18815E-16
1.28232E-16
1.47787E-16
2.20192E-16
6.12338E-16
8.08087E-16
1.58868E-15
1.79493E-15
3.57496E-15
3.99319E-15
4.44619E-15
4.60373E-15
6.8719E-15
2.37932E-14
2.80598E-14
3.1411E-14
3.48625E-14
6.75305E-14
1.34569E-13
1.36191E-13
1.54307E-13
1.91728E-13
3.29801E-13
3.55297E-13
4.71932E-13

Table 7: Top 30 biologic processes altered by ablation compared to surgery alone
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Symbol: Name
SLC12A1: solute carrier
family 12
(sodium/potassium/chloride
transporters), member 1
MMP12: matrix
metallopeptidase 12
(macrophage elastase)
KIAA1199: KIAA1199

Fold
Change
12.311

Notes

Location

Pathways

Processes

Diseases

Interactions

1

Molecular
Function
Transporter

Plasma
Membrane

1

5

10

1

9.899

1

Peptidase

Extracellular
Space

7

43

22

4

8.481

1

Other

Cytoplasm

0

0

10

0

ALDOB: aldolase B, fructosebisphosphate
UMOD: uromodulin

8.273

1

Enzyme

Cytoplasm

4

0

6

3

7.863

1

Other

0

21

13

0

DPT: dermatopontin

6.98

1

Other

0

3

9

1

IBSP: integrin-binding
sialoprotein
MT1G: metallothionein 1G

6.282

1

Other

0

6

12

3

6.104

1

Other

Extracellular
Space
Extracellular
Space
Extracellular
Space
Unknown

0

0

12

1

MMP9: matrix
metallopeptidase 9
(gelatinase B, 92kDa
gelatinase, 92kDa type IV
collagenase)
LRRC15: leucine rich repeat
containing 15
COMP: cartilage oligomeric
matrix protein
KNG1: kininogen 1

5.225

1

Peptidase

Extracellular
Space

21

113

48

34

5.201

1

Other

0

1

9

1

5.073

0

Other

0

8

3

0

4.931

1

Other

8

72

19

7

AQP2: aquaporin 2
(collecting duct)
CCL19: chemokine (C-C
motif) ligand 19
CHI3L1: chitinase 3-like 1
(cartilage glycoprotein-39)
C7: complement component
7
MS4A1: membranespanning 4-domains,
subfamily A, member 1
LGI2: leucine-rich repeat LGI
family, member 2
PLA2G7: phospholipase A2,
group VII (platelet-activating
factor acetylhydrolase,
plasma)
RANBP3L: RAN binding
protein 3-like

4.591

0

Transporter

1

2

1

2

4.338

1

Cytokine

2

127

10

3

3.988

1

Enzyme

1

50

21

4

3.847

1

Other

2

2

17

2

3.708

1

Other

Plasma
Membrane
Extracellular
Space
Extracellular
Space
Plasma
Membrane
Extracellular
Space
Extracellular
Space
Extracellular
Space
Plasma
Membrane

0

37

20

3

3.524

1

Other

0

0

9

0

3.511

1

Enzyme

Extracellular
Space
Extracellular
Space

8

30

7

0

3.502

0

Other

Unknown

0

0

0

0

Table 8: Top 20 most upregulated genes comparing ablation to surgery alone
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Symbol: Name
PLA1A: phospholipase A1
member A
ARHGEF28: Rho guanine
nucleotide exchange factor
(GEF) 28
HOXA4: homeobox A4
PDE11A: phosphodiesterase
11A
PLA2G16: phospholipase A2,
group XVI
VLDLR: very low density
lipoprotein receptor
EGFR: epidermal growth
factor receptor
ARHGEF35: Rho guanine
nucleotide exchange factor
(GEF) 35
KIF21A: kinesin family
member 21A
SPINK13: serine peptidase
inhibitor, Kazal type 13
(putative)
MT1L: metallothionein 1L
(gene/pseudogene)
SERPINI1: serpin peptidase
inhibitor, clade I
(neuroserpin), member 1
C19orf33: chromosome 19
open reading frame 33

Fold
Change
-2.259

Notes
0

Molecular
Function
Enzyme

Location

Pathways

Processes

Diseases

Extracellula
r Space
Cytoplasm

1

1

0

Interaction
s
2

-2.273

1

Other

0

7

9

0

-2.382

1

Nucleus

0

8

15

0

1

transcriptio
n regulator
Enzyme

-2.472

Cytoplasm

6

2

12

0

-2.488

0

Enzyme

Nucleus

8

7

0

0

-2.507

0

Transporter

2

6

4

0

-2.515

1

Kinase

36

83

23

40

-2.64

0

Other

Plasma
Membrane
Plasma
Membrane
Unknown

0

0

0

0

-2.718

1

Other

Cytoplasm

0

0

11

0

-2.768

0

Other

Unknown

0

0

0

0

-2.836

0

Other

Cytoplasm

0

0

5

2

-2.866

0

Other

Extracellula
r Space

0

4

6

1

-2.922

0

Other

Nucleus

0

0

0

0

Table 9: Top 10 most downregulated genes comparing ablation to surgery alone
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To help confirm quality control and to enhance our analysis we were assisted by the
Bioinformatics Department at UT MD Anderson Cancer Center. In this analysis, one sample in
the post ablation group was found to be significantly different than the rest and was excluded
from additional analysis. The quality control analysis is shown in Table 10 and Figure 1
revealing a significant outlier. As a result, of the four post treatment samples remaining 3 were
from patients who received radiofrequency ablation and 1 had received cryoablation prior to
nephrectomy. Using a beta-uniform mixture model or BUM model, the distribution of p values
was tabulated and the generated histogram is found in Figure 2. In this model, the assumption is
there will be no significant interesting genes and the p-values should fall in a normal distribution
curve. If the p-values all segregate close to 0, this indicates a higher likelihood of detecting
important findings 57. Figure 3 displays the most significant core pathways altered. In this table,
the –log of the p value is represented on the Y axis, with higher bar graphs indicating greater
likelihood of significance. The color of the bar graph indicates the Z-score in relationship to
standard value of the canonical signaling pathways. If the bar is orange the pathway is
significantly upregulated. If the bar is white the pathway is similar to normal observed signaling
levels. If the bar is blue it is significantly down-regulated and if the bar is gray the baseline
signaling characteristics are not well defined at this time. Finally the ratio represented refers to
the number of genes significantly up-regulated or down-regulated and is divided by the total
number of genes in the pathway.
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Sample 1

Samples 2

Samples 3

Sample 4

Sample 5

Sample 1

1

0.9

0.9

0.4

0.9

Sample 2

0.9

1

0.9

0.4

0.9

Sample 3

0.9

0.9

1

0.4

0.9

Sample 4

0.4

0.4

0.4

1

0.4

Sample 5

0.9

0.9

0.9

0.4

1

Table 10: Quality control (QC) assessment shows that one sample of the post treatment group
appears to be an outlier and one of the samples in the pretreatment is distinct from other samples.
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Figure 1: QC assessment shows that one sample of the post treatment group appears to be an
outlier and one of the samples in the pretreatment is distinct from other samples.

30

Figure 2: Histogram of p values BUM model: 4 post treatment samples were compared with 9
nephrectomy only samples.
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Figure 3: Core pathways altered. IPA core pathway analysis. Settings: p value cutoff: 0.05; Log
ratio cutoff 0.4.
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In an attempt to gain more uniformity, the Ingenuity pathway analysis was performed
excluding the cryoablation sample and included the three samples treated with radiofrequency
ablation prior to nephrectomy again using nephrectomy only as the comparator arm. In this
analysis, Figure 4 is the histogram from the BUM model and shows significant improvement as
compared to the BUM model generated in Figure 2, with the majority of p values approaching 0.
Figure 5 shows the core pathways altered and uses the same approach for analysis described
above for Figure 3. The top pathway was “Connection between Innate and Adaptive Immune
Cells”. The majority of the top pathways involve immune cell signaling, maturation,
differentiation, trafficking, and inflammation. Table 11 lists the top regulatory upstream
molecules and their downstream targets. All molecules included on this list except one (SND1),
directly target immune signaling.
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Figure 4: Histogram of p values: 3 post treatment samples were compared with 9 nephrectomy
only samples.
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Figure 5: Core pathways altered. IPA core pathway analysis. Settings: p value cutoff: 0.05; Log
ratio cutoff 0.4. The most significant pathway altered is “communication between innate and
adaptive immune cells” pathway.

35

Table 11: Upstream pathway regulators; the columns are as follows: Gene name of the upstream
regulator, log ratio of the upstream regulator in the dataset, activation z-score, and target
molecules.
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Immunohistochemistry (IHC)
The tumoral and peritumoral infiltration of cytoplasmic staining CD4+ cells were
tabulated for patients who underwent nephrectomy alone (control), patients who underwent any
ablation procedure prior to nephrectomy (treatment), patients who underwent a distant ablation
to a site other than the renal primary tumor (distant), and patients who underwent an ablation to
the kidney and later had a nephrectomy (local). Figure 6, Figure 7, and Figure 8 show examples
of IHC staining for CD3, CD4, CD8, CD20, CD57, CD68, FoxP3, Granzyme B, PD-1, PD-L1
tumoral cells, PD-L1 immune cells. Slides were selected to involve normal renal tissue, the
invasive margin, and tumoral tissue, Figures 6-8 represent examples of slides used in analysis.
In Figure 6, CD3 is a pan marker for T cells capturing both CD4 and CD8 T cell populations.
CD4 and CD8 are T cell subset markers and CD20 is a marker for B cell populations. In Figure
7, CD45RO stains for T cell memory subset, CD57 stains for NK cells, and CD68 for
macrophages. In Figure 8, FoxP3 is stained to capture a T cell regulatory subset of cells,
Granzyme B stains cytotoxic cells, PD-1 stains immune cells expressing this immune check
point, and PD-L1 stains both tumoral and immune cells expressing this immune check point
ligand.
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Figure 6: Immunohistochemistry staining: CD3 T cell marker, CD4 subset of T cells, CD8
subset of T cells, CD20 marker of B cells. Each slide contained a section of normal renal
architecture (N), the invasive margin (IM), and the center of tumor (CT). Cells were stained and
the number of stained cells/mm3 per 5 high power fields (HPF) at 20x magnification was
quantified.
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Figure 7: Immunohistochemistry staining: CD45RO a stain for a subset of T cell memory cells,
CD57 a stain for natural killer (NK) cells, CD68 a stain for macrophages. Each slide contained a
section of normal renal architecture (N), the invasive margin (IM), and the center of tumor (CT).
Cells were stained and the number of stained cells/mm3 per 5 high power fields (HPF) at 20x
magnification was quantified.
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Figure 8: Immunohistochemistry: FoxP3 a stain for regulatory T cells, Granzyme B a stain for
active cytotoxic T cells, PD-1 I(programmed death receptor 1), PD-L1 (programmed death
receptor ligand 1). Each slide contained a section of normal renal architecture (N), the invasive
margin (IM), and the center of tumor (CT). Cells were stained and the number of stained
cells/mm3 per 5 high power fields (HPF) at 20x magnification was quantified.
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Figures 9 through 14 represent the analysis of IHC that were initially performed by Dr.
Priya Rao. The IHC stains included CD4, CD8, CD45RO, Granzyme B, FoxP3, KP-1 (a stain
for macrophages). In Figures 9 through 14, the entire population of patients was analyzed in the
top graph and only patients who received nephrectomy within 1 year (control and ablation
patients) were evaluated in the bottom graph. No significant differences were detected in CD4+
T cells (Figure 9), CD8+T cells (Figure 10), CD45RO+T cells (Figure 11), Forkhead P3 (FoxP3)
(Figure 12) Granzyme B (Figure 13), or KP-1 (CD68) (Figure14) in the entire population or
analyzing patients who received nephrectomy within 1 year following ablation.
In 2014, the methods of enumerating staining immune cells were changed to be
consistent across all studies using the immunotherapy platform. The changes included having
each slide capture a section of normal renal architecture, the invasive margin, and the tumor. In
an effort to be consistent with future studies, we selected appropriate tumor blocks, recut tissue,
and re-stained slides using the new immunotherapy platform selected stains. Figures 15 thru 17
represent the percent staining of cells in normal tissue (N) referring to renal tissue that is not
intimately involved with tumor, the invasive margin (IM), and the center of tumor (CT). Control
refers to patients who were treated with nephrectomy alone and ablation refers to patients who
received ablation. We selected only patients who received nephrectomy within one year
following an ablation procedure for this repeat analysis. Unfortunately, 3 patients’ tissue blocks
had significant fixation artifacts and were unable to be used. We are attempting to locate at this
time whether additional tissue blocks are available. In Figure 15, no differences were detected
by student’s T test when comparing CD3+T cells, CD4+ T cells, CD8+ T cells, and CD45RO+ T
cells between patients treated with nephrectomy alone or ablation later followed by
nephrectomy. The portions of the slide labeled as N, IM, and CT, revealed no differences
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between the two groups of patients. In Figure 16, CD20+ B cells, CD68+ macrophages, FoxP3
(regulatory T cell stain), and granzyme B (cytotoxic T cell stain) were analyzed and no
detectable difference was found between groups. In Figure 17, a difference between PD-1
staining was found between the IM and a trend toward difference in the CT was detected, with
more staining being detected in patients treated with ablation compared to nephrectomy alone.
Other analysis in Figure 12 included the PD-L1 staining in tumoral and immune cells, and the
PD-L1 H score did not find a significant difference between the two groups of patients.
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Figure 9: Initial Immunohistochemistry for CD4+ T cells. The top figure includes all patients.
Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who underwent an
ablation procedure prior to nephrectomy (n=16) , distant refers to ablation to the kidney
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed
by later nephrectomy (n=13). The bottom figure includes patients who had ablation followed by
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4).
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared
to control. ns = non-significant, * = p<0.05.
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Figure 10: Initial Immunohistochemistry for CD8+ T cells. The top figure includes all patients.
Control refers to nephrectomy alone (n=9) , Treatment refers to any patient who underwent an
ablation procedure prior to nephrectomy (n=16) , distant refers to ablation to the kidney
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed
by later nephrectomy (n=13). The bottom figure includes patients who had ablation followed by
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4).
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared
to control. ns = non-significant, * = p<0.05.
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Figure 11: Initial Immunohistochemistry for CD45RO+ T cells. The top figure includes all
patients. Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who
underwent an ablation procedure prior to nephrectomy (n=16) , distant refers to ablation to the
kidney followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ
followed by later nephrectomy (n=13). The bottom figure includes patients who had ablation
followed by nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3),
local (n=4). Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group
compared to control. ns = non-significant, * = p<0.05.
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Figure 12: Initial Immunohistochemistry for FoxP3+ cells. The top figure includes all patients.
Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who underwent an
ablation procedure prior to nephrectomy (n=16) , distant refers to ablation to the kidney
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed
by later nephrectomy (n=13). The bottom figure includes patients who had ablation followed by
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4).
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared
to control. ns = non-significant, * = p<0.05.
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Figure 13: Initial Immunohistochemistry for Granzyme B+ cells. The top figure includes all
patients. Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who
underwent an ablation procedure prior to nephrectomy (n=16) , distant refers to ablation to the
kidney followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ
followed by later nephrectomy (n=13). The bottom figure includes patients who had ablation
followed by nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3),
local (n=4). Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group
compared to control. ns = non-significant, * = p<0.05.
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Figure 14: Initial Immunohistochemistry for KP1+ cells, which represents a stain for
macrophages. The top figure includes all patients. Control refers to nephrectomy alone (n=9) ,
Ablation refers to any patient who underwent an ablation procedure prior to nephrectomy (n=16),
distant refers to ablation to the kidney followed by nephrectomy at a later date (n=3), local refers
to ablation of a distant organ followed by later nephrectomy (n=13). The bottom figure includes
patients who had ablation followed by nephrectomy within 1 year: control (n=9), treatment
(ablation) (n=7), distant (n=3), local (n=4). Kruskal Wallis test is top line, Dunn’s multiple
comparisons test between each group compared to control. ns = non-significant, * = p<0.05.
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Figure 15: Updated IHC using new immunotherapy platform protocol. Density N refers to
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients
who received ablation procedure prior to nephrectomy. Groups are compared with student t test.
CD3 T cell marker, CD4 subset of T cells, CD8 subset of T cells, CD45RO a stain for a subset of
T cell memory cells.
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Figure 16: Updated IHC using new immunotherapy platform protocol. Density N refers to
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients
who received ablation procedure prior to nephrectomy. Groups are compared with student t test.
CD20 B cell stain, CD68 macrophage stain, FoxP3 stain for regulatory subset, Gr-B granzyme B
for cytotoxic cells.
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Figure 17: Updated IHC using new immunotherapy platform protocol. Density N refers to
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients
who received ablation procedure prior to nephrectomy. Groups are compared with student t test.
PD-1 program death receptor 1, PD-L1 programmed death receptor ligand 1 expressing immune
cells, PD-L1 program death receptor ligand 1 expressing tumor cells, and PD-L1 H score.
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Flow cytommetry
Figures 18 through 32 represent the flow cytommetry analysis for patients analyzed
prospectively after ablation to a primary renal cell carcinoma in the kidney. Day 0 (D0) reflects
a baseline blood draw prior to ablation procedure and could occur within a one month period
prior to the procedure. Day 1 (D1) reflects the immediate day following procedure while the
patient remained hospitalized. Day 28 (D28) is the blood draw obtained 4 weeks following
procedure at a scheduled return visit with urology. Day 180 is the blood draw obtained at 6
months following the ablation procedure. Several patients had a blood draw at 4 months and 1
year following the procedure without the 6 month blood draw. These blood draws were
excluded from the analysis. In each of the figures, A represents the gating used for flow
cytommetry. B represents all patients with baseline (day 0), day 1, day 28, and day 180 blood
draws with percentage of positive cells. Kruskal-Wallis (unmatched data) and Dunn’s multiple
comparisons tests were used to determine statistical significance. C represents patients who had
all four scheduled blood draws, and D represents individual patients with 3 blood draws at
baseline, day 1, and day 28. For both C and D, Friedman’s test (matched data at each time
point) and Dunn’s multiple comparisons tests were used to determine statistical significance.
CD4+T cells (Figure 18), CD8+T cells (Figure 19), CD19+B cells (Figure 20), CD4+ICOShi T
cells (Figure 21), CD8+ICOShi T cells (Figure 22), CD4+CD45RO+T cells (Figure 28), linCD4+CD45RO+CD62L+CCR7- T cells representing T effector memory (Figure 29), linCD4+CD45RO+CD62L+CCR7+ T cells representing T central memory (Figure 30), macrophage
(Figure 31), and myeloid derived suppressor cells (Figure 32) did not show significant
differences between baseline and later time points. The regulatory immune subsets included
CD4+FoxP3+ T cells (Figure 23), CD8+FoxP3+ T cells (Figure 24), CD4+CD25+FoxP3+ T cells
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(Figure 25), CD4+CD25+Lap+ T cells (Figure 26), and CD4+CD25+CD127-T cells(Figure 27).
The CD4+FoxP3+ T cells did show a statistically significant change between groups and a
statistically significant increase between the day 1 blood draw that returned almost to baseline by
the day 28 blood draw. Similarly, CD4+CD25+Lap+ T cells showed a statistically significant
change between groups and a statistically significant increase between the day 1 blood draw that
returned almost to baseline by the day 28 blood draw. Both the CD4+CD25+FoxP3+ T cells and
the CD4+CD25+CD127- T cells had similar trends that approached, but did not reach
significance.
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Figure 18 Flow cytommetry analysis CD4+ T cells: A represents the gating used for flow
cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day 1,
day 28, and day 180 blood draws with percentage of positive CD4+ T cells. Kruskall-Wallis and
Dunn’s multiple comparisons tests were used to determine statistical significance. C represents
patients who had blood draws at 4 time points, and D represents individual patients with 3 blood
draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and Dunn’s multiple
comparisons tests were used to determine statistical significance. (ns = not significant, * =
p<0.05)
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Figure 19 Flow cytommetry analysis CD8+ T cells: A represents the gating used for flow
cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day 1,
day 28, and day 180 blood draws with percentage of positive CD8+ T cells. Kruskall-Wallis and
Dunn’s multiple comparisons tests were used to determine statistical significance. C represents
patients who had blood draws at 4 time points, and D represents individual patients with 3 blood
draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and Dunn’s multiple
comparisons tests were used to determine statistical significance. (ns = not significant, * =
p<0.05)
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Figure 20 Flow cytommetry analysis CD19+ B cells: A represents the gating used for flow
cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day 1,
day 28, and day 180 blood draws with percentage of positive CD19+ B cells. Kruskall-Wallis
and Dunn’s multiple comparisons tests were used to determine statistical significance. C
represents patients who had blood draws at 4 time points, and D represents individual patients
with 3 blood draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and
Dunn’s multiple comparisons tests were used to determine statistical significance. (ns = not
significant, * = p<0.05)
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Figure 21 Flow cytommetry analysis CD4+ ICOShi T cells: A represents the gating used for
flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day
1, day 28, and day 180 blood draws with percentage of positive CD4+ ICOShi T cells. KruskallWallis and Dunn’s multiple comparisons tests were used to determine statistical significance. C
represents patients who had blood draws at 4 time points, and D represents individual patients
with 3 blood draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and
Dunn’s multiple comparisons tests were used to determine statistical significance. (ns = not
significant, * = p<0.05)

57

Figure 22 Flow cytommetry analysis CD8+ ICOShi T cells: A represents the gating used for
flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day
1, day 28, and day 180 blood draws with percentage of positive CD8+ ICOShi T cells. KruskallWallis and Dunn’s multiple comparisons tests were used to determine statistical significance. C
represents patients who had blood draws at 4 time points, and D represents individual patients
with 3 blood draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and
Dunn’s multiple comparisons tests were used to determine statistical significance. (ns = not
significant, * = p<0.05)
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Figure 23: Flow cytommetry analysis CD4+ FoxP3+ T cells: A represents the gating used for
flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day
1, day 28, and day 180 blood draws with percentage of positive CD4+ FoxP3+ T cells. KruskallWallis and Dunn’s multiple comparisons tests were used to determine statistical significance. C
represents patients who had blood draws at 4 time points, and D represents individual patients
with 3 blood draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and
Dunn’s multiple comparisons tests were used to determine statistical significance. (ns = not
significant, * = p<0.05)
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Figure 24 Flow cytommetry analysis CD8+ FoxP3+ T cells Figure: A represents the gating used
for flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0),
day 1, day 28, and day 180 blood draws with percentage of positive CD8+ FoxP3+ T cells.
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical
significance. C represents patients who had blood draws at 4 time points, and D represents
individual patients with 3 blood draws at baseline, day 1, and day 28. For both C and D,
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 25 Flow cytommetry analysis CD4+ CD25+ FoxP3+ T cells: A represents the gating used
for flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0),
day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+ FoxP3+ T
cells. Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical
significance. C represents patients who had blood draws at 4 time points, and D represents
individual patients with 3 blood draws at baseline, day 1, and day 28. For both C and D,
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 26 Flow cytommetry analysis CD4+ CD25+ Lap+ T cells: A represents the gating used
for flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0),
day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+ Lap+ T cells.
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical
significance. C represents patients who had blood draws at 4 time points, and D represents
individual patients with 3 blood draws at baseline, day 1, and day 28. For both C and D,
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, p<0.05)
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Figure 27 Flow cytommetry analysis CD4+ CD25+ CD127 - T cells: A represents the gating
used for flow cytommetry, samples tested in triplicate. B represents all patients with baseline
(day 0), day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+
CD127 - T cells. Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine
statistical significance. C represents patients who had blood draws at 4 time points, and D
represents individual patients with 3 blood draws at baseline, day 1, and day 28. For both C and
D, Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 28 Flow cytommetry analysis CD4+ CD45RO+ Tcells: A represents the gating used for
flow cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day
1, day 28, and day 180 blood draws with percentage of positive CD4+ CD45RO+ T cells.
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical
significance. C represents patients who had blood draws at 4 time points, and D represents
individual patients with 3 blood draws at baseline, day 1, and day 28. For both C and D,
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 29 Flow cytommetry analysis TEM (T Effector Memory) linCD4+CD45RO+CD62L+CCR7- T cells: A represents the gating used for flow cytommetry,
samples tested in triplicate. B represents all patients with baseline (day 0), day 1, day 28, and
day 180 blood draws with percentage of positive TEM T cells. Kruskall-Wallis and Dunn’s
multiple comparisons tests were used to determine statistical significance. C represents patients
who had blood draws at 4 time points, and D represents individual patients with 3 blood draws at
baseline, day 1, and day 28. For both C and D, Friedman’s test and Dunn’s multiple
comparisons tests were used to determine statistical significance. (ns = not significant, * =
p<0.05)
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Figure 30 Flow cytommetry analysis TCM (T Central Memory) linCD4+CD45RO+CD62L+CCR7+T cells: A represents the gating used for flow cytommetry,
samples tested in triplicate. B represents all patients with baseline (day 0), day 1, day 28, and
day 180 blood draws with percentage of positive TCM cells. Kruskall-Wallis and Dunn’s
multiple comparisons tests were used to determine statistical significance. C represents patients
who had 4 time point blood draws, and D represents individual patients with 3 blood draws at
baseline, day 1, and day 28. For both C and D, Friedman’s test and Dunn’s multiple
comparisons tests were used to determine statistical significance. (ns = not significant, * =
p<0.05)
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Figure 31 Macrophage: A represents the gating used for flow cytommetry, samples tested in
triplicate. B represents all patients with baseline (day 0), day 1, day 28, and day 180 blood draws
with percentage of positive CD4+ T cells. Kruskall-Wallis and Dunn’s multiple comparisons
tests were used to determine statistical significance. C represents patients who had blood draws
at 4 time points, and D represents individual patients with 3 blood draws at baseline, day 1, and
day 28. For both C and D, Friedman’s test and Dunn’s multiple comparisons tests were used to
determine statistical significance. (ns = not significant, * = p<0.05)
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Figure 32 MDSC (Myeloid derived suppressor cells): A represents the gating used for flow
cytommetry, samples tested in triplicate. B represents all patients with baseline (day 0), day 1,
day 28, and day 180 blood draws with percentage of positive CD4+ T cells. Kruskall-Wallis and
Dunn’s multiple comparisons tests were used to determine statistical significance. C represents
patients who had 4 time point blood draws, and D represents individual patients with 3 blood
draws at baseline, day 1, and day 28. For both C and D, Friedman’s test and Dunn’s multiple
comparisons tests were used to determine statistical significance. (ns = not significant, * =
p<0.05)
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Cytokine Studies
The results of serum cytokine studies are represented in Figures 33 through 43. All 10
cytokines were measured prospectively in pg/mL and displayed on the x-axis in Figure 33 with
the mean cytokine level at three time points represented by three bar graphs. The first bar
represents day 0 or baseline, the second bar represents 24 hours or day 1 following the ablation,
the third bar represents day 28 after the ablation. IL-6 was the cytokine that exhibited the
highest levels in the serum at each time point and did exhibit statistically significant change from
baseline to day 1. Figure 34-43 show 7 patients who had matched baseline, 24 hour, and 28 day
blood draws. The most significant change was in IL-6 with a significant increase between
baseline and day 1 based on the Dunn’s multiple comparison test. The group difference based on
the Kruskal Wallis test of IL-6 approached significance with p=0.052. IL-10 did show a
significant difference between groups using the Friedman test with a trend downward from
baseline to day 1 to day 28. IL-12p70 also found a significant difference between day 1 and day
28 and between groups. However, the level of IL-12p70 detected in the serum was very low
approaching the level of the first standard and the confidence to report this finding is small.
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Figure 33: Post ablation levels of cytokines. Each cytokine is represented with 3 bars, the first
bar corresponds to the baseline blood draw, bar 2 is day 1 following procedure, bar 3 is day 28
blood draw.
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Figure 34: Serum interferon γ level at baseline (D0), day 1 (D1), and day 28 (D28). Each
patient is represented with a different colored symbol. As each patient had 3 blood draws, the
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 35: Serum IL-12p70 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient
is represented with a different colored symbol. The Friedman’s test and Dunn’s multiple
comparison tests were used to determine statistical significance. (ns = not significant, * =
significant with p<0.05)
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Figure 36: Serum IL-10 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)

73

Figure 37: Serum IL-13 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance.
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Figure 38: Serum IL-17 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)
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Figure 39: Serum IL-2 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)
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Figure 40: Serum IL-4 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)
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Figure 41: Serum interferon γ level at baseline (D0), day 1 (D1), and day 28 (D28). Each
patient is represented with a different colored symbol. As each patient had 3 blood draws, the
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical
significance. (ns = not significant, * = p<0.05)
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Figure 42: Serum IL-6 level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)
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Figure 43: Serum TNF-α level at baseline (D0), day 1 (D1), and day 28 (D28). Each patient is
represented with a different colored symbol. As each patient had 3 blood draws, the Friedman’s
test and Dunn’s multiple comparisons tests were used to determine statistical significance. (ns =
not significant, * = p<0.05)
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IV.

Discussion
The hypothesis of thermal ablation procedures cause a significant local inflammatory

response leading to an immunogenic gene signature that will be confirmed with detectable
changes in immune cells identified in tissue with immunohistochemistry and in the peripheral
circulation was not established in the studies presented above. The first aim examining a
retrospective cohort of patients treated with thermal ablation following nephrectomy compared
to nephrectomy alone did appear to find an inflammatory, immunogenic signature. However,
finding the inflammatory, immunogenic signature required removal of one sample due to it
having significant different properties than the rest and not meeting quality control metrics and
our decision to exclude one patient treated with cryoablation leaving only three samples from
two patients treated with radiofrequency ablation. As a result, the confidence in these findings is
limited despite the BUM modeling and the significance detected by extremely small p-values.
Gene signatures have previously been proposed in melanoma implicating the importance of
connectivity between the innate and adaptive immune response 58,59 60.
The upstream molecules found during the Ingenuity analysis are known mediators of
inflammation including cytokines, chemokines, toll like receptors, members of the Janus
Kinase/Signal Transducer and Activator of Transcription (JAK/Stat) signaling pathway.
Triggering Receptor Expressed on Myeloid Cells 1 or TREM1 was found to have significant
activation with a p value of (1.73E-09). TREM1 is known to be expressed on neutrophils,
monocytes, and platelets 61

62

. It has been found to be related by Bruton’s Tyrosine Kinase

(BTK) and Non-T cell activation linker (NTAL) 63. TREM1 has been described as playing an
important role in human sepsis 64 62 and blunting both toll like receptor 4 and TREM1 has been
associated with blunting of the sometimes lethal sepsis response in animal modeling. TREM1
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has been described to be an innate receptor for necrotic cell death a mechanism of cell death
described in ablation procedures. TREM1 could be further explored in animal models with
ablation procedures to understand if blocking TREM1 signaling could augment any protective
effect from ablation or disrupt connectivity between innate and adaptive immune signaling.
Gene microarray analysis has exploded in the field of oncology. Given the amount of
information generated from a study, generating a clinically meaningful signature that is
duplicated by other data sets is challenging. Some of the initial work in gene microarray analysis
was carried out by Takahashi et al and published in 2001 65. In this work, two distinct signatures
were identified that clearly segregated patients into good and poor prognostic categories. In a
study by Kosari et al. gene microarray could clearly distinguish normal tissue adjuvant to renal
carcinoma, indolent and aggressive biology tumors. The microarray analysis was validated using
quantitative reverse transcription-PCR (RT-PCR)
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. One of the lead candidate genes to

discriminate survival was the aptly named gene survivin. In our datasets, survivin was not
significant. In 2005, Subramanian proposed using gene expression enrichment analysis to focus
on gene sets to help interpret the results of the large amount of data emerging from genomic
analysis
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. Using this approach Maruschke et al. found 16 significantly upregulated or

downregulated gene sets that were capable of differentiating high grade from low grade clear cell
renal cell carcinomas 68. More recently, molecular signatures known as ccA and ccB have been
proposed and were validated in The Cancer Genome Atlas (TCGA) in clear cell renal cell
carcinoma 69 70. In our analysis, the biologic processes, pathways, and individual genes were all
dominated by the immune system. If the inflammation and immunogenicity can be harnessed to
prime the immune system prior to additional immune based therapy as has been found in animal
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modeling with melanoma and prostate cancer, this could rapidly be brought to clinic and
potentially be explored in a wide variety of tumor types.
The second aim of the project was to determine in a retrospective cohort of patients if
there is a correlation between the gene signature produced with thermal ablation followed by
nephrectomy with changes detected in immunohistochemistry for specific immune cell subsets,
comparing to patients treated with nephrectomy alone. Based on our available analysis, we were
unable to correlate the findings of our gene signature with differences in immune infiltrate
between the two groups of patients studied.
Interpreting the results of the immunohistochemistry retrospectively is challenging. First
considering patients who underwent a renal ablation followed later by nephrectomy, there was a
wide range in time between the two procedures. Will an ablation procedure have lasting immune
impact six years after performed? Will an ablation procedure have a local impact on the immune
system 2 months after procedure? These studies are difficult to perform prospectively in this
patient population as the purpose of treating with ablative procedures is to provide definitive
local control. As a result, patients who receive a partial or radical nephrectomy in this context
are viewed as local treatment failure of the RFA or cryoablation. The exception to this role
would be patients who have multiple masses and require subsequent surgery for a growing
alternative mass as can often be the case in patients with Von Hippel Lindau or other instances in
hereditary causes of multiple complex renal masses/cysts. In the case of a solitary renal lesion,
cryoablation and RFA are known to have local control rates approaching 90% and have been
reported in single series to be greater than 95% in renal tumors less than 3cm 71. As a result, the
studies of our patients may reflect a more aggressive or different local biology than seen in
typical series of solitary small renal tumors. Also the impact of immune infiltration may be
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significantly different in a patient who has local disease under control versus a patient who has
failed previous ablation procedure.
Also adding a layer of complexity is that retrospective data has emerged in regards to the
local and systemic immunity being vastly different in the context of higher staged and more
aggressive tumor biology. As a result, drawing conclusions from patients with largely T1a or
T1b tumors and extrapolating to patients with locally advanced or metastatic disease is likely to
be flawed. In 2003, Bromwich et al. noted that patients with increased CD4+T cells within their
tumor at the time of surgery had worse survival which was found to hold independent prognostic
influence on multivariable analysis and was important regardless of tumor grade 72. Similar
findings by Nakano et al, when analyzing 221 patients treated with primary nephrectomy for
renal cell carcinoma where both increased CD4+ and CD8+ T cell infiltrates correlated with
shortened survival, more advanced stage and tumor grade 73. In a study by Cozar et al, looking
at both the tumor infiltrating lymphocyte (TIL) population and peripheral blood immune cells in
patients with RCC undergoing nephrectomy, increasing stage was associated with diminished
TIL presence of NK cells, lower populations of effector memory cells which were characterized
as CCR5/CXCR3/CD4+ cells, and an increased population of CD25+CD4+ cells consistent with a
Treg population 74. In a study of 70 patients with RCC undergoing nephrectomy, 16 patients had
matched peripheral blood and TIL. The authors observed high levels of the chemokine receptors
CCR5, CXCR3, and CXCR6 on TILS corresponding to chemokines expressed in renal cell
tissue. Also observed where higher Treg populations with these chemokine receptors in the TIL
population leading to a proposed mechanism of recruitment of these cells into the tumors for
immune escape 75.

84

As increased understanding of important T cell subsets has expanded across research
fields, additional studies have found that increased levels of regulatory T cell subsets defined by
both flow cytommetry, IHC, and confirmed with functional assays has found a correlation
between the presence of T regulatory cells and outcome in patients with renal cell carcinoma 76.
In a large series from the Mayo clinic, the presence of CD4+CD25+FoxP3+ tumor infiltrating
cells was not associated with poor outcome, but the presence of CD4+CD25+FoxP3- tumor
infiltrating cells was associated with poor prognosis 77.
The increased presence of Treg population in TIL population has been associated with
worsening survival in patients treated with cytokine based immunotherapy 78,79. Jensen et al.
analyzed the TIL population in patients treated with high dose interleukin-2 treatment and found
patients who had significant increases in Treg TIL after IL-2 therapy had worse survival and the
only long term survivors observed on study were those who had low baseline Treg population
and only a modest rise in Treg population following IL-2 therapy. Griffiths found a higher
population of Treg cells in circulation as compared to normal donors and an inferior survival in
patients with RCC with elevated levels of Treg cells. 78
In our analysis of the immunohistochemistry data, limited differences were found in
immune cell staining between patients treated with nephrectomy alone or ablation followed by
nephrectomy. It is unclear if this is a function of both populations having active tumor at the
time of resection, significant lag between ablation and nephrectomy, or lack of power given
small sample size.

Interestingly, a difference was detected in PD-1 staining in the IM, however

this does appear to be influenced by one patient who had significantly higher levels than both
control and other treated tumor analyzed.
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The third and final aim of the project was to determine in a prospective cohort of patients
if thermal ablation produces detectable changes in peripheral blood immune cell subsets and
cytokine levels that can be detected over one day, four weeks, and a 6 month timeframe. In a
similar fashion as in our retrospective immunohistochemistry studies, the inflammatory gene
signature was not confirmed in cytokine or flow cytommetry studies. The only potential
exceptions were subtle changes noted in potential T regulatory cell populations and early trends
in serum cytokine levels of IL-6 and IL-10.
In the flow cytommetry portion of our study, the most interesting observations occurred
within the potential T regulatory (Treg) populations. However, defining the Treg population in
this setting is limited and challenging without the additional functional assays. In a seminal
work in 1995, Sakaguchi et al. identified CD4 cells expressing the IL-2 receptor alpha-chain
(CD25) were crucial in protecting against auto-immunity and in graft rejection in mice 80.
Further work by this group found that depletion of CD4+CD25high lead to tumor rejection in mice
81

. The CD4+CD25high cells population when depleted and transferred into other mice can

produce autoimmune disease 82 Work by Baecher-Allen et al. further characterized human
CD4+CD25high population of T cells finding they were capable of suppressing other effector T
cells, were resistant to activation, but were capable of being activated when plated with anti-CD3
antibody with CD28 cross-linking which resulted in loss of regulatory function. Importantly,
when these cells were co-cultured with monoclonal antibodies directed against immune check
point inhibitors CTLA-4, PD-1, and PD-L1, the CD4+CD25high continued to have regulatory
function 83. The identification of FoxP3 expression in T regulatory cells was reported by Hori et
al in mice and Walker et al. in humans in 2003 84 85. In humans, Walker found that peripheral
CD4+CD25- T cells were capable of being induced to express FoxP3, which differed from mice.
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Once induced, these cells were capable of suppressing other effector T cells through direct
contact, which was not dependent on cytokine.

Work by Chen et al. found that in addition to

Treg cells produced in the thymus, peripheral CD4+CD25- could be induced to become Treg
cells under the influence of transforming growth factor beta (TGF-β) and T cell receptor (TCR)
stimulation. In addition FoxP3 could be induced under the influence of TGF-β 86. Yagi et al.
went on to show that human peripheral T cell CD4+CD25- transduced to express FoxP3 went on
to up-regulate CTLA-4 and CD25 and exhibited Treg phenotype 87. Findings by Morgan et al,
questioned the expression of FoxP3 as a marker of regulatory T cells only as FoxP3 mRNA
could be detected in all T cell clones and stimulated cells expressing FoxP3 were capable of
producing interferon gamma and proliferation consistent with effector T cell population 88 . Qiao
et al. further identified the role of CD4+CD25+FoxP3+ T cells labeled as natural T regulatory
cells or nTregs by co-culturing with CD4+CD25- cells with IL-4 and anti-CD3 was capable of
inducing a population of cells that were labeled as induced T regulatory cells or iTregs that did
not express FoxP3 89. Using a RAG 2-/- murine model that has no naturally occurring
CD4+CD25+ T cells, daily peptide vaccine resulted in a significant population of
CD4+CD25+FoxP3+ T cells with suppressive function 90.
The accurate identification of a human T regulatory cell is challenging. Part of the
limitation revolves around the processing of cells required to identify the intracellular marker
FoxP3. Due to the need to permeabilize the cell surface, once stained for FoxP3, functional
assays are not possible. The combination of dendritic cell vaccine and low dose interleukin-2
resulted in nearly immediate rise in CD4+CD25highFoxP3+ T cells 91 as detected in peripheral
blood, which reduced after 8 days but did not return to baseline. In patients with metastatic
melanoma and metastatic RCC treated with high dose interleukin 2 therapy, patients who

87

achieved sustained response had diminished levels of Treg cells detected in peripheral blood
following therapy, with those who had progressive disease had the opposite trend 92. van der
Vliet et al. reported high dose IL-2 diminished peripheral dendritic cell subsets, NK cells, while
increasing CD4(+)CD25(+) T cells, which included the CD4(+)Foxp3(+) T cell subset 93.
However, interestingly the CD4+CD25+ T cells were less capable of regulating other T cells as
compared to freshly harvested CD4+CD25+ T cells.
A different marker of Treg cells CD4+CD25+CD117- has been suggested by several
groups. However in work done in Dr. Sharma’s laboratory, patients treated with anti-CTLA-4
based immune therapy that had cells with the surface markers CD4+CD25+CD117- did not have
discriminatory function between T effector and T regulatory cells 94. In this work,
CD4+CD25+Lap+ cells were found to accurately identify a subset of T regulatory cells as
determined by in vitro functional assays from cells taken from human subjects treated on a
clinical trial. Other groups have suggested using FoxP3 promoter methylation status as a way of
accurately identifying Treg cells in human studies 95
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.

In our prospective analysis of circulating serum cytokines, interleukin-6 (IL-6) was the
highest at baseline and significantly increased after ablation therapy. Elevated IL-6 levels have
been associated with poor outcome in mRCC treated with high dose IL-2 97. Compared to
healthy controls, Yoshida et al. reported IL-6 levels increase with increasing tumor stage and
grade and is significantly elevated in patients with metastatic disease98. In addition, TNF-α
levels were elevated compared to controls, but not increase in a stage or grade dependence as
witnessed with IL-6. In a large multicenter trial evaluating IL-2 and IFN-α, elevated levels of
IL-6 were associated with inferior survival 99. Guida et al. compared serum cytokines and Creactive protein in healthy controls and patients with mRCC treated with subcutaneous IL-2 both
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at baseline and during treatment 100. C-reactive protein, IL-6, IL-8 were all significantly higher
in patients with mRCC compared to healthy controls and greater elevation was associated with
poor outcome. Conversely, elevated IL-12 levels were associated with improved outcome. On
multivariate analysis, only CRP and IL-12 maintained significance. Using baseline cytokine,
circulating angiogenic factors, and the Memorial Sloan Kettering risk grouping, an improved
prognostic risk score could be established to predict patients who would survive five years with
mRCC 101. The cytokines included IL-12p40, IL-6, and IL-5.
The changes found in the gene microarray portion of the study serve as a potential
fingerprint indicating a locally immunogenic environment created by an ablation procedure.
IHC was unable to capture significant differences in immune cell populations, but the
retrospective analysis and the cohort of patients selected, progression of tumor after ablation and
differing times between procedure and nephrectomy, likely did not serve as a representative
patient population to detect such changes. Significant changes were also not noted in peripheral
blood immune cell subtypes by flow cytommetry and serum cytokine analysis. However, the
time frame of collecting these blood draws one day following the procedure, one month, and six
months likely are not the optimal time to analyze for changes in either the innate or adaptive
immune response. To have ideally studied this question, an increased patient population would
be required. Nephrectomy or biopsy would occur within weeks or short months following the
ablation. Timed blood draws at baseline, day1, week 1, week 2, week 4, and then at month 3 and
month 6 would be collected in all patients. Unfortunately having patients undergo this degree of
blood testing is likely not reasonable in this setting.
The above study was completed to help us analyze changes both within tissue and in the
blood of patients treated with ablation in anticipation of an upcoming trial pairing cryoablation
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with tremelimumab (anti-CTLA-4 antibody) in patients with metastatic renal cell carcinoma. As
the study does not contain a cryoablation only arm, our group wanted to better define changes
related to ablation alone to help with interpretation of data from the trial. The use of
combination immunotherapy is underway in a variety of malignancies. Ablation procedures may
serve as a way to prime the immune system to better pair with immune check point blockade.
V.

Conclusions:
Thermal ablation changes the immune microenvironment as detected by gene microarray.

These changes could not be confirmed by immunohistochemistry or in peripheral blood studies
using flow cytommetry and cytokine analysis. However, small sample sizes, early staged
clinical disease, and the potential selection of a subset of patients with aggressive biology could
have impacted our findings. Understanding the impact of cryoablation or radiofrequency alone
will be important in interpretation of clinical trial information in future studies.
VI.

Limitations
The limitations in this analysis are numerous. The tissue collected was performed on a

retrospective basis leading to the potential for sample collection bias. Tumor tissue was
collected predominately from early stage RCC patients, but several patients who developed
metastatic disease were included leading to significant differences in the patient population.
Ideally, limiting the patient selection to early stage localized disease would have helped
interpretation of results. Also significant differences in time between tissue acquisition and
staining occurred, allowing for the potential for batch effects. In the clinical trial of
tremelimumab plus cryoablation versus tremelimumab alone, samples will be analyzed rapidly
reducing the risk of batch effects. In the gene microarray analysis, out of the five post treatment
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samples submitted for analysis, one was deemed a significant outlier and was excluded and one
was eventually excluded due to being a different procedure. As a result only three samples
remained, of which two were from the same patient potentially biasing the information obtained.
Also, differences related to immune cell infiltration and in percentage of stroma versus tumor
cells in each sample are not characterized and have the potential to lead to significant differences
given such limited samples. In future analysis, having additional control sample biopsies from
multiple sites of the same tumor may help control for these differences and lead to more
confidence in interpreting the results. In the cytokine studies, significant differences in sample
storage time existed. In a study by de Jager et al, storage time leads to cytokine degradation
potentially impacting the results of our study 102.
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